Chemotherapy has a proven palliative role in advanced gastric cancer, significantly improving quality of life and prolonging survival compared with best supportive care alone. Although there is no standard of treatment, 5-fluorouracil (5-FU)/cisplatin doublets and the combination of epirubicin, cisplatin and 5-FU (ECF) have both achieved response rates in the range of 40-50% and median overall survival of 8-10 months. Either could claim the status of a reference regimen. Single-agent irinotecan achieved response rates (RR) of 18% and 23% in phase II studies, and 48% when combined with cisplatin. However, a randomized trial of irinotecan plus cisplatin versus irinotecan plus 5-FU/folinic acid (FA) showed that the latter regimen achieved a higher RR (34% versus 28%) and significantly longer median survival (10.7 versus 6.9 months). Hematological toxicity was lower with the irinotecan/5-FU/FA combination. This regimen has therefore been taken forward into a randomized phase III comparison against a 5-FU/cisplatin doublet. Use of irinotecan-based combinations should also be investigated as an adjuvant treatment (probably in combination with radiotherapy) and in the neoadjuvant setting.
Introduction
Randomized trials have demonstrated that chemotherapy for advanced gastric cancer improves quality of life and extends survival by 4-6 months compared with best supportive care alone [1] [2] [3] [4] . In the palliation of stage IV gastric cancer, there is no shortage of treatment options. Single agents with proven activity in the first-line setting include 5-fluorouracil (5-FU), cisplatin and etoposide. These drugs have all been used in a variety of combinations, along with doxorubicin, epirubicin, methotrexate and mitomycin. However 5-FU has been the cornerstone of treatment.
Is there a reference regimen?
Single-agent 5-FU remains in widespread use in the USA, and (with the exception of the EAP combination of etoposide, doxorubicin and cisplatin) 5-FU is a component of all the major multidrug regimens that have been studied.
A decade of research has left us with three broad conclusions. First, the use of 5-FU plus doxorubicin plus high-dose methotrexate (FAMTX) is superior to the FAM combination of 5-FU, doxorubicin and mitomycin C. In the randomized 212-patient study by Wils et al. [5] , the response rate (RR) with FAM was 9% while that with FAMTX was 41% (P <0.0001), and the median survivals were 29 and 42 weeks, respectively (P = 0.004) (Table 1) .
Secondly, the EAP regimen is associated with considerable toxicity. In a comparison of EAP with FAMTX, the 33% RR with FAMTX was higher than the 20% RR with EAP, but the more salient finding was the toxic death rate in the EAP group (Table 1) [6].
Thirdly, there is some justification for considering that the combination of epirubicin with cisplatin and 5-FU (ECF) is the most active available. Webb et al. [7] compared ECF with FAMTX, and showed ECF to be significantly superior in terms of both RR (45% versus 21%; P = 0.0002) and survival (8.9 versus 5.7 months; P = 0.0009) ( Table 1) .
However, when interpreting these data it should be noted that one-third of patients included in the overall survival analysis had locally advanced disease and were therefore not stage IV cases by conventional criteria. One-quarter of the 47 locally advanced patients treated with ECF underwent curative surgery after neoadjuvant chemotherapy. Finally, more than one-third of patients in the trial had adenocarcinoma of the esophagus or gastroesophageal junction, which may be in essence a disease different from classical gastric cancer.
These considerations may help explain why many oncologists consider that the doublet of 5-FU/cisplatin has as good a claim as ECF to the role of treatment standard. In the trial by Webb et al. [7] , use of 5-FU/cisplatin was associated with an 8 month overall survival. The combination has also been studied by many other groups, employing a range of doses and every 2, 3 or 4 week schedules. RRs of 40% to 50% and median survival durations in excess of 9-10 months have been reported (Table 2 ) [8] [9] [10] [11] [12] [13] .
These results are evidence of progress, but there remains an urgent need for new and more active drugs for the treatment of advanced gastric cancer. Agents in development for this indication include irinotecan, the taxanes (docetaxel and paclitaxel) and the epothilones.
Irinotecan in phase II studies
Several phase II studies of single-agent irinotecan in gastric cancer have been conducted. In a European trial, Köhne et al. [12] administered irinotecan 350 mg/m 2 every 3 weeks, and found an RR of 20% (including two complete responses among the 35 ii38 evaluable patients). A somewhat higher RR (of 23%) was reported in a Japanese phase II trial of irinotecan monotherapy [14] . In a second Japanese phase II study, irinotecan 70 mg/m 2 every 2 weeks was given together with cisplatin 80 mg/m 2 on day 1 every 4 weeks [15] . An RR of 48% was seen in 44 evaluable patients, who survived for a median of 10.1 months. In this study, the RR was 59% for patients who had not received prior chemotherapy, and the overall survival was 322 days in the 29 patients who had received no prior chemotherapy. Previous phase I/II experience had established that the dose-limiting toxicity when combining irinotecan with cisplatin is hematological.
Irinotecan plus cisplatin versus irinotecan plus 5-FU in advanced disease
On the basis of these studies, a large phase II/III trial (study V306) was undertaken [16] . In the initial phase II part of the trial, a total of 146 patients with histologically proven adenocarcinoma of the stomach or gastroesophageal junction were randomized to receive either irinotecan 200 mg/m 2 plus cisplatin 60 mg/m 2 every 3 weeks, or irinotecan 80 mg/m 2 weekly plus 5-FU/FA according to the Arbeitsgemeinschaft Internische Onkologie (AIO) regimen (FA was given at 500 mg/m 2 infused over 2 h followed by 5-FU 2000 mg/m 2 infused over 22 h , weekly for 6 weeks, with 1 week between cycles) (Figure 1) .
The aim of the initial part of the study was to select one of the two irinotecan combinations for comparison against a reference 5-FU/cisplatin regimen in the phase III portion of the trial. This decision was to be made on the basis of safety and efficacy in the first 60 patients evaluable in each arm of the study.
Toxicities
Neutropenia and its complications were more frequent when irinotecan was combined with cisplatin than when it was combined with 5-FU/FA (Table 3) . Diarrhea was more frequent among patients administered irinotecan with 5-FU. However, the incidence of other non-hematological toxicities was similar across groups. Overall, both combinations could be considered well tolerated.
Efficacy
The overall RR with the irinotecan/5-FU/FA combination was 34% (a complete response was seen in two patients). This RR was somewhat higher than the RR of 26% (one complete response) seen with irinotecan/cisplatin. In time to progression and median survival, the irinotecan/5-FU/FA combination was clearly superior to the irinotecan/cisplatin doublet (Table 4 ). This superiority was evident also in the proportion of patients alive at 1 year: 44% with irinotecan/5-FU/FA and 23% in the irinotecan/cisplatin group. On the basis of these efficacy and safety data, the combination of irinotecan with 5-FU/FA was clearly the appropriate combination to test against a reference regimen of 5-FU/cisplatin. This randomized phase III comparison is now closed to accrual, with 171 patients treated in each arm. Its results are awaited with great interest. They will be considered alongside results from an ongoing Japanese trial that has chosen to make somewhat different comparisons. Following evidence that S1 (an oral anti-cancer drug containing tegafur, 5-chloro-2,4-dihydroxypiridine and potassium oxonate) achieved a 45% RR in advanced or recurrent gastric cancer in a late phase II trial [17] , the ongoing Japanese study will compare irinotecan plus cisplatin versus S1 alone and versus 5-FU alone.
Neoadjuvant and adjuvant settings
In an ongoing neoadjuvant trial in Japan, patients with para-aortic node metastases receive two to three courses of cisplatin 80 mg/m 2 on day 1 plus irinotecan 70 mg/m 2 on days 1 and 15. Those who become resectable are operated on, while those who remain unresectable move off-protocol. The primary end point of the study is 3-year survival.
Such a study would not be feasible in Europe or North America, where randomized trials have failed to show that routine use of D2 ii40 dissection results in improved short-term outcome or long-term survival [18, 19] . These issues are discussed in greater detail elsewhere in this volume. In considering the potential for adjuvant chemotherapy, it should be noted that the group of patients eligible for potentially curative surgery is extremely heterogeneous, ranging from stage IB T1-N1-M0 disease through stage IIIA T2-N2 disease to stage IIIA T4-N0 [20] . In the light of the Intergroup 0116 finding that adjuvant 5-FU-based chemoradiotherapy is associated with improved survival, it would be appropriate to study the impact of irinotecan plus radiotherapy in these settings.
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